Mind Medicine (MindMed) Aktie

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Stanley D. Glick, and Jamon Alexander Rahn in 2019 and is headquarter in Toronto, Canada.